During the past decade, Weill Cornell Cancer Center conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Weill Cornell Cancer Center" are "Advanced Malignancies" (1 trials), "Hematologic Malignancies" (1 trials) and "Myeloid Malignancy" (1 trials). Many other conditions were trialed in "Weill Cornell Cancer Center" in a lesser frequency.

Most popular intervention types in "Weill Cornell Cancer Center" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "APR-246" (1 trials), "Azacitidine" (1 trials), "CDX-1401" (1 trials), "CDX-1401 in combination with Resiquimod and/or Poly-ICLC" (1 trials) and "IPI-493" (1 trials). Other intervention names were less common.

The vast majority of trials in "Weill Cornell Cancer Center" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Weill Cornell Cancer Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Weill Cornell Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Weill Cornell Cancer Center, 3 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".